In this feature, I was given three sets of survey data, gathered from patients, physicians and payers, regarding the problems accessing certain specialized drugs. They can be prohibitively expensive and challenging to lay hands on. My job was to discuss why this is and find out – What’s being done to address this? What more can be done?
It’s not a story where there are a lot of immediate answers, but it’s definitely an area that needs talking about. I hope you enjoy the article!